GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Onward Medical NV (STU:63E) » Definitions » Current Accrued Expense

Onward Medical NV (STU:63E) Current Accrued Expense : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Onward Medical NV Current Accrued Expense?

Onward Medical NV's Current Accrued Expense for the quarter that ended in Dec. 2023 was €0.00 Mil.


Onward Medical NV Current Accrued Expense Historical Data

The historical data trend for Onward Medical NV's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Onward Medical NV Current Accrued Expense Chart

Onward Medical NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Accrued Expense
Get a 7-Day Free Trial - - - - -

Onward Medical NV Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Onward Medical NV Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Onward Medical NV Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Onward Medical NV's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Onward Medical NV (STU:63E) Business Description

Traded in Other Exchanges
Address
High Tech Campus 32, Noord-Braban, Eindhoven, NH, NLD, NL-5656 AE
Onward Medical NV is a medical technology company developing and commercializing therapies to enable functional recovery for people with spinal cord injury. It has developed two programmable neurostimulation platforms: an implantable system, ARCIM, and a non-invasive, transcutaneous system, ARCEX. The company has selected the United states and four European markets: Germany, France, the UK and the Netherlands to create a customer base.

Onward Medical NV (STU:63E) Headlines

No Headlines